NYON, Switzerland, August 25 MymeticsCorporation (OTC: MYMX), will be holding an important conference call onWednesday August 27th 2008 at 1 PM New York Time to update all shareholderson the recent progress of the company, the June 30th 2008 Form 10-Q and toaddress recent press articles.
You may join the call Toll Free from the US at +1-866-591-4361 PIN 815726 and from Europe at +41-800-329-326 PIN 815 726.
Mymetics' primary objective is to develop vaccines and therapies toprevent and treat the effects of certain retroviruses and other infectiousdiseases, including the human immunodeficiency virus, or HIV, the virus thatleads to acquired immunodeficiency syndrome, or AIDS. Mymetics has alsorecently acquired from a close scientific partner an advanced malaria vaccineproject currently in phase Ib clinical trials. Additional applications ofMymetics's research include potential treatments and/or vaccines for humanoncoviral leukemias, multiple sclerosis, and organ transplantation.Contact: Anthony Jessop Senior Vice President Mymetics, Inc. Phone North America: +1-303-800-6606 E-Mail: firstname.lastname@example.org
SOURCE Mymetics Corporation